34D.F · DiaSorin S.p.A

-

Please sign in to comment on 34D.F

1 Comment

Admin

4 years, 1 month ago

DiaSorin S.p.A is currently in a long term uptrend where the price is trading 0.3% above its 200 day moving average.

From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.6.

DiaSorin S.p.A's total revenue rose by 49.7% to $271M since the same quarter in the previous year.

Its net income has increased by 74.1% to $85M since the same quarter in the previous year.

Finally, its free cash flow grew by 71.0% to $105M since the same quarter in the previous year.

Based on the above factors, DiaSorin S.p.A gets an overall score of 5/5.

Exchange	F
CurrencyCode	EUR
ISIN	IT0003492391
Sector	Healthcare
Industry	Diagnostics & Research

Beta	0.4
Market Cap	5B
PE Ratio	29.81
Target Price	None
Dividend Yield	1.2%

ABOUT

DiaSorin S.p.A

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic LIAISON chemiluminescence analyzers under LIAISON XL and LIAISON XS name; and Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. The company was founded in 1968 and is headquartered in Saluggia, Italy.

34D.F · DiaSorin S.p.A

-

DiaSorin S.p.A

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest DiaSorin S.p.A using a moving average strategy